(Q43267035)

17 November 2017

title

Role of gemcitabine in the treatment of ovarian cancer (English)

1 reference

17 November 2017

1 reference

Fadi Abushahin

1

1 reference

17 November 2017

Peter G Rose

series ordinal

2

1 reference

17 November 2017

publication date

1 May 2007

1 reference

17 November 2017

1 reference

17 November 2017

volume

3

1 reference

17 November 2017

issue

3

1 reference

17 November 2017

page(s)

279-290

1 reference

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

High-dose carboplatin in refractory ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Carboplatin: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Preclinical in vivo activity of a combination gemcitabine/liposomal doxorubicin against cisplatin-resistant human ovarian cancer (A2780/CDDP).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Gemcitabine-carboplatin-paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

First-line gemcitabine and carboplatin in advanced ovarian carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.3.3.279

21 January 2018

Identifiers

DOI

10.2217/17455057.3.3.279

1 reference

17 November 2017

1 reference